Atossa Genetics
Yahoo Finance • last year
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
SEATTLE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast... Full story
Yahoo Finance • last year
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Achieved significant enrollment milestones in ongoing Phase 2 clinical trials Four ongoing Phase 2 studies evaluating (Z)-endoxifen, including recently announced study in DCIS Ended third quarter 2023 with $94.0 million of cash and cash eq... Full story
Yahoo Finance • last year
Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors
SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast... Full story
Yahoo Finance • last year
Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023
SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on b... Full story
Yahoo Finance • last year
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
SEATTLE, July 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast... Full story
Yahoo Finance • last year
Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial
SEATTLE, July 10, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast... Full story
Yahoo Finance • 2 years ago
Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer
SEATTLE, July 06, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on br... Full story
Yahoo Finance • 2 years ago
Atossa Therapeutics announces 30% enrollment for Phase 2 I-Spy breast cancer clinical trial
New York --News Direct-- Atossa Therapeutics Inc Atossa Therapeutics CEO Steven Quay joined Proactive's Natalie Stoberman to discuss the latest progress in its Phase 2 I-SPY 2 clinical trial where six patients have been dosed with Atossa’... Full story
Yahoo Finance • 2 years ago
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
SEATTLE and SAN FRANCISCO, June 28, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with... Full story
Yahoo Finance • 2 years ago
Atossa Therapeutics Announces $10M Stock Repurchase Program
SEATTLE, June 27, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on br... Full story
Yahoo Finance • 2 years ago
Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023
SEATTLE, June 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on br... Full story
Yahoo Finance • 2 years ago
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
SEATTLE, June 21, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on br... Full story
Yahoo Finance • 2 years ago
Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC
SEATTLE, June 14, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on br... Full story
Yahoo Finance • 2 years ago
Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
SEATTLE, June 12, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on br... Full story
Yahoo Finance • 2 years ago
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
Two Phase 2 trials investigating (Z)-endoxifen in neoadjuvant setting initiated and are enrolling patientsFull enrollment of Phase 2 KARISMA mammographic breast density study expected by end of 2023Ended first quarter 2023 with $103.9 mill... Full story
Yahoo Finance • 2 years ago
Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focu... Full story
Yahoo Finance • 2 years ago
Atossa Therapeutics to Participate in Tribe Public’s Webinar Event “Redefining Breast Cancer Prevention and Treatment”
Virtual webinar scheduled for Thursday, May 4 at 8:00 am pacific / 11:00 am easternMeet with Atossa’s Founder and CEO, Steven Quay, M.D., Ph.D.Event is open to the public – registration available at ATOS5423.TribePublic.com SEATTLE, April... Full story
Yahoo Finance • 2 years ago
Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update
SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced fi... Full story
Yahoo Finance • 2 years ago
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial
SEATTLE and SAN FRANCISCO, March 21, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, an... Full story
Yahoo Finance • 2 years ago
Atossa to Present at the Sidoti Small-Cap Virtual Conference
SEATTLE, March 15, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced th... Full story
